Qure.ai, a global healthcare AI leader, announced the completion of a $65 million Series D funding round. The funds will accelerate the company’s expansion into the US and other markets, boost investment in foundational AI models, and enable strategic acquisitions in the med-tech space. The round attracted new investors, including Lightspeed, 360 ONE Asset, and Merck Global Health Innovation Fund, alongside existing backers like Novo Holdings and HealthQuad.
Founded in 2016, Qure.ai’s AI-powered healthcare solutions are deployed in over 90 countries, making critical disease management more efficient. With 18 FDA-cleared indications and European certification, Qure.ai has become a trusted medical imaging AI partner for healthcare organizations globally, focusing on diseases such as TB, lung cancer, and stroke.
The new funding will propel Qure.ai’s mission to improve global healthcare accessibility, especially in underserved regions. CEO Prashant Warier highlighted the company’s partnerships with top pharma firms and its aim to reach a billion patients through AI-driven diagnostics and early treatment solutions.
Click here to read the original news story.